EMAS position statement: Managing obese postmenopausal women

Maturitas

Volumn 66, Issue 3, 2010, Pages 323-326

  Lambrinoudaki, Irene ^a   Brincat, Marc ^a   Erel, C Tamer ^a   Gambacciani, Marco ^a   Moen, Mette H ^a   Schenck Gustafsson, Karin ^a   Tremollieres, Florence ^a   Vujovic, Svetlana ^a   Rees, Margaret ^a   Rozenberg, Serge ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Breast cancer; Hormone treatment; Menopause; Obesity; Stroke; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CLONIDINE; CONJUGATED ESTROGEN; DYDROGESTERONE; ESTRADIOL; GABAPENTIN; PROGESTERONE; PROTHROMBIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TIBOLONE;

ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; GENE MUTATION; HORMONAL THERAPY; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; OBESITY; OSTEOPOROSIS; PREVALENCE; QUALITY OF LIFE; RISK ASSESSMENT; TREATMENT DURATION; UROGENITAL TRACT ATROPHY; UROGENITAL TRACT DISEASE; VENOUS THROMBOEMBOLISM;

BREAST NEOPLASMS; DRUG ADMINISTRATION ROUTES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; OBESITY; POSTMENOPAUSE; PROGESTINS; RISK FACTORS; SOCIETIES, MEDICAL; VENOUS THROMBOEMBOLISM;

EID: 77953021388     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.03.025     Document Type: Article

References (34)

1. Evangelista O., and McLaughlin M.A. Review of cardiovascular risk factors in women. Gend Med 6 Suppl. 1 (2009) 17-36
2. Pérez J.A., Garcia F.C., Palacios S., and Pérez M. Epidemiology of risk factors and symptoms associated with menopause in Spanish women. Maturitas 62 1 (2009) 30-36
3. Lobo R.A. Metabolic syndrome after menopause and the role of hormones. Maturitas 60 1 (2008) 10-18
4. Thurston R.C., Sowers M.R., Chang Y., et al. Adiposity and reporting of vasomotor symptoms among midlife women: the study of women's health across the nation. Am J Epidemiol 167 1 (2008) 78-85
5. Thurston R.C., Sowers M.R., Sternfeld B., et al. Gains in body fat and vasomotor symptom reporting over the menopausal transition: the study of women's health across the nation. Am J Epidemiol 170 6 (2009) 766-774
6. Schenck-Gustafsson K. Risk factors for cardiovascular disease in women. Maturitas 63 3 (2009) 186-190
7. Page J.H., Rexrode K.M., Hu F., Albert C.M., Chae C.U., and Manson J.E. Waist-height ratio as a predictor of coronary heart disease among women. Epidemiology 20 3 (2009) 361-366
8. Yatsuya H., Folsom A.R., Yamagishi K., et al. Race- and sex-specific associations of obesity measures with ischemic stroke incidence in the Atherosclerosis Risk in Communities (ARIC) Study. Stroke Jan 21 (2010)
9. Rexrode K.M., Hennekens C.H., Willett W.C., et al. A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 277 19 (1997) 1539-1545
10. Cushman M., Kuller L.H., Prentice R., et al. Women's health initiative investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 292 13 (2004) 1573-1580
11. Renehan A.G., Tyson M., Egger M., Heller R.F., and Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371 9612 (2008) 569-578
12. Pichard C., Plu-Bureau G., Neves-E C.M., and Gompel A. Insulin resistance, obesity and breast cancer risk. Maturitas 60 1 (2008) 19-30
13. Hodis H.N., and Mack W.J. Coronary heart disease and hormone replacement therapy after the menopause. Climacteric 12 Suppl. 1 (2009) 71-75
14. Wassertheil-Smoller S., Hendrix S.L., Limacher M., et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289 20 (2003) 2673-2684
15. Hendrix S.L., Wassertheil-Smoller S., Johnson K.C., et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 113 20 (2006) 2425-2434
16. Canonico M., Plu-Bureau G., Lowe G.D., and Scarabin P.Y. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 336 7655 (2008) 1227-1231
17. Gompel A., Rozenberg S., Barlow D.H., and EMAS board members. The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas 61 3 (2008) 227-232
18. Kuhl H. Breast cancer risk in the WHI study: the problem of obesity. Maturitas 51 1 (2005) 83-97
19. Helfand M., Buckley D.I., Freeman M., et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 151 7 (2009) 496-507
20. Tan Y.Y., Gast G.C., and van der Schouw Y.T. Gender differences in risk factors for coronary heart disease. Maturitas Nov 6 (2009) [Epub ahead of print]
21. D'Agostino Sr. R.B., Vasan R.S., Pencina M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117 6 (2008) 743-753
22. Wickramasinghe S.R., DeFilippis A.P., Lloyd-Jones D.M., and Blumenthal R.S. A convenient tool to profile patients for generalized cardiovascular disease risk in primary care. Am J Cardiol 103 8 (2009) 1174-1177
23. Stuedal A., Ma H., Bjorndal H., et al. Postmenopausal hormone therapy with estradiol and norethisterone acetate and mammographic density: findings from a cross-sectional study among Norwegian women. Climacteric 12 (2009) 248-258
24. Grady D., Vittinghoff E., Lin F., et al. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. Menopause 14 (2007) 391-396
25. Grodsten F., Manson J.E., Colditz G.A., et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133 (2000) 933-941
26. Jick H., Derby L.E., Myers M.W., et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348 9033 (1996) 981-983
27. Canonico M., Oger E., Plu-Bureau G., et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 115 7 (2007) 840-845
28. Canonico M., Fournier A., Carcaillon L., et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 30 2 (2010) 340-345
29. Campagnoli C., Ambroggio S., Lotano M.R., and Peris C. Progestogen use in women approaching the menopause and breast cancer risk. Maturitas 62 4 (2009) 338-4230
30. Fournier A., Mesrine S., and Boutron-Ruault M.C. Clavel-ChapelonF estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?. J Clin Oncol 27 (2009) 5138-5143
31. Curb J.D., Prentice R.L., and Bray P.F. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 166 (2006) 772-780
32. Canonico M., Oger E., Conard J., et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 4 6 (2006) 1259-1265
33. Cummings S.R., Ettinger B., Delmas P.D., et al. The effects of tibolone in older postmenopausal women. N Engl J Med 359 7 (2008 Aug 14) 697-708
34. Shen W., and Stearns V. Treatment strategies for hot flushes. Expert Opin Pharmacother 10 May(7) (2009) 1133-1144